APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis B Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis B Drug Market Outlook and Growth Opportunities 2026

Report ID 17399791042 January 2026193 pages

Choose your research edition.

Industry ResearchHepatitis B Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis B Drug Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Hepatitis B Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis B Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis B Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Hepatitis B Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatitis B Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatitis B Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis B Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatitis B Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatitis B Drug market include Bristol-Myers Squibb, Gilead Sciences, Merck & Co. Inc., Mitsubishi Tanabe Pharma, AbbVie, GlaxoSmithKline, Roche, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hepatitis B Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis B Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis B Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hepatitis B Drug market.

Hepatitis B Drug Segment by Company

Bristol-Myers Squibb

Gilead Sciences

Merck & Co. Inc.

Mitsubishi Tanabe Pharma

AbbVie

GlaxoSmithKline

Roche

Novartis

Johnson & Johnson

Hepatitis B Drug Segment by Type

Tenofovir

Telbivudine

Lamivudine

Entecavir

Adefovir

Others

Hepatitis B Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Others

Hepatitis B Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hepatitis B Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hepatitis B Drug key companies, revenue, market share, and recent developments.

3. To split the Hepatitis B Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hepatitis B Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis B Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis B Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis B Drug industry.

Chapter 3: Detailed analysis of Hepatitis B Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hepatitis B Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hepatitis B Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis B Drug Industry Trends Table 2. Hepatitis B Drug Industry Drivers Table 3. Hepatitis B Drug Industry Opportunities and Challenges Table 4. Hepatitis B Drug Industry Restraints Table 5. Global Hepatitis B Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis B Drug Revenue Share by Company (2021-2026) Table 7. Global Hepatitis B Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hepatitis B Drug Key Company Manufacturing Base & Headquarters Table 9. Global Hepatitis B Drug Company, Product Type & Application Table 10. Global Hepatitis B Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hepatitis B Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tenofovir Table 15. Significant Companies of Telbivudine Table 16. Significant Companies of Lamivudine Table 17. Significant Companies of Entecavir Table 18. Significant Companies of Adefovir Table 19. Significant Companies of Others Table 20. Global Hepatitis B Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Hepatitis B Drug Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Hepatitis B Drug Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Hepatitis B Drug Sales Value Share by Type (2021-2026) Table 24. Global Hepatitis B Drug Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Pharmacies Table 26. Significant Companies of Retail Pharmacies & Drug Stores Table 27. Significant Companies of Others Table 28. Global Hepatitis B Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Hepatitis B Drug Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Hepatitis B Drug Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Hepatitis B Drug Sales Value Share by Application (2021-2026) Table 32. Global Hepatitis B Drug Sales Value Share by Application (2027-2032) Table 33. Global Hepatitis B Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hepatitis B Drug Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Hepatitis B Drug Sales Value Share by Region (2021-2026) Table 36. Global Hepatitis B Drug Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Hepatitis B Drug Sales Value Share by Region (2027-2032) Table 38. Global Hepatitis B Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Hepatitis B Drug Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Hepatitis B Drug Sales Value Market Share by Country (2021-2026) Table 41. Global Hepatitis B Drug Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Hepatitis B Drug Sales Value Market Share by Country (2027-2032) Table 43. Bristol-Myers Squibb Company Information Table 44. Bristol-Myers Squibb Business Overview Table 45. Bristol-Myers Squibb Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Bristol-Myers Squibb Hepatitis B Drug Product Portfolio Table 47. Bristol-Myers Squibb Recent Development Table 48. Gilead Sciences Company Information Table 49. Gilead Sciences Business Overview Table 50. Gilead Sciences Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Gilead Sciences Hepatitis B Drug Product Portfolio Table 52. Gilead Sciences Recent Development Table 53. Merck & Co. Inc. Company Information Table 54. Merck & Co. Inc. Business Overview Table 55. Merck & Co. Inc. Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Merck & Co. Inc. Hepatitis B Drug Product Portfolio Table 57. Merck & Co. Inc. Recent Development Table 58. Mitsubishi Tanabe Pharma Company Information Table 59. Mitsubishi Tanabe Pharma Business Overview Table 60. Mitsubishi Tanabe Pharma Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Mitsubishi Tanabe Pharma Hepatitis B Drug Product Portfolio Table 62. Mitsubishi Tanabe Pharma Recent Development Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AbbVie Hepatitis B Drug Product Portfolio Table 67. AbbVie Recent Development Table 68. GlaxoSmithKline Company Information Table 69. GlaxoSmithKline Business Overview Table 70. GlaxoSmithKline Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. GlaxoSmithKline Hepatitis B Drug Product Portfolio Table 72. GlaxoSmithKline Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Hepatitis B Drug Product Portfolio Table 77. Roche Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis Hepatitis B Drug Product Portfolio Table 82. Novartis Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Hepatitis B Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Hepatitis B Drug Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Hepatitis B Drug Product Image Figure 2. Global Hepatitis B Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis B Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatitis B Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tenofovir Image Figure 8. Telbivudine Image Figure 9. Lamivudine Image Figure 10. Entecavir Image Figure 11. Adefovir Image Figure 12. Others Image Figure 13. Global Hepatitis B Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Hepatitis B Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Hepatitis B Drug Sales Value Share by Type (2021-2032) Figure 16. Hospital Pharmacies Image Figure 17. Retail Pharmacies & Drug Stores Image Figure 18. Others Image Figure 19. Global Hepatitis B Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hepatitis B Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Hepatitis B Drug Sales Value Share by Application (2021-2032) Figure 22. Global Hepatitis B Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Hepatitis B Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Hepatitis B Drug Sales Value (2021-2032) & (US$ Million) Figure 25. North America Hepatitis B Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Hepatitis B Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Hepatitis B Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Hepatitis B Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Hepatitis B Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Hepatitis B Drug Sales Value (2021-2032) & (US$ Million) Figure 31. South America Hepatitis B Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Hepatitis B Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Hepatitis B Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Hepatitis B Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Tenofovir
  • Telbivudine
  • Lamivudine
  • Entecavir
  • Adefovir
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma
  • AbbVie
  • GlaxoSmithKline
  • Roche
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hepatitis B Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hepatitis B Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hepatitis B Drug Market Dynamics
  1. 2.1 Hepatitis B Drug Industry Trends
  2. 2.2 Hepatitis B Drug Industry Drivers
  3. 2.3 Hepatitis B Drug Industry Opportunities and Challenges
  4. 2.4 Hepatitis B Drug Industry Restraints
3 Hepatitis B Drug Market by Company
  1. 3.1 Global Hepatitis B Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis B Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis B Drug Company Ranking (2024-2026)
  4. 3.4 Global Hepatitis B Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Hepatitis B Drug Company Product Type and Application
  6. 3.6 Global Hepatitis B Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hepatitis B Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hepatitis B Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hepatitis B Drug Market by Type
  1. 4.1 Hepatitis B Drug Type Introduction
  2. 4.1.1 Tenofovir
  3. 4.1.2 Telbivudine
  4. 4.1.3 Lamivudine
  5. 4.1.4 Entecavir
  6. 4.1.5 Adefovir
  7. 4.1.6 Others
  8. 4.2 Global Hepatitis B Drug Sales Value by Type
  9. 4.2.1 Global Hepatitis B Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Hepatitis B Drug Sales Value by Type (2021-2032)
  11. 4.2.3 Global Hepatitis B Drug Sales Value Share by Type (2021-2032)
5 Hepatitis B Drug Market by Application
  1. 5.1 Hepatitis B Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies & Drug Stores
  4. 5.1.3 Others
  5. 5.2 Global Hepatitis B Drug Sales Value by Application
  6. 5.2.1 Global Hepatitis B Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatitis B Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Hepatitis B Drug Sales Value Share by Application (2021-2032)
6 Hepatitis B Drug Regional Value Analysis
  1. 6.1 Global Hepatitis B Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis B Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hepatitis B Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hepatitis B Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hepatitis B Drug Sales Value (2021-2032)
  7. 6.3.2 North America Hepatitis B Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hepatitis B Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Hepatitis B Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hepatitis B Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hepatitis B Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hepatitis B Drug Sales Value (2021-2032)
  16. 6.6.2 South America Hepatitis B Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hepatitis B Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hepatitis B Drug Sales Value Share by Country, 2025 VS 2032
7 Hepatitis B Drug Country-level Value Analysis
  1. 7.1 Global Hepatitis B Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis B Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hepatitis B Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hepatitis B Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hepatitis B Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hepatitis B Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hepatitis B Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Hepatitis B Drug Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Hepatitis B Drug Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 Merck & Co. Inc.
  14. 8.3.1 Merck & Co. Inc. Company Information
  15. 8.3.2 Merck & Co. Inc. Business Overview
  16. 8.3.3 Merck & Co. Inc. Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Inc. Hepatitis B Drug Product Portfolio
  18. 8.3.5 Merck & Co. Inc. Recent Developments
  19. 8.4 Mitsubishi Tanabe Pharma
  20. 8.4.1 Mitsubishi Tanabe Pharma Company Information
  21. 8.4.2 Mitsubishi Tanabe Pharma Business Overview
  22. 8.4.3 Mitsubishi Tanabe Pharma Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mitsubishi Tanabe Pharma Hepatitis B Drug Product Portfolio
  24. 8.4.5 Mitsubishi Tanabe Pharma Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Hepatitis B Drug Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Hepatitis B Drug Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Hepatitis B Drug Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Hepatitis B Drug Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson Hepatitis B Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson Hepatitis B Drug Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst